CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.81B, above the global median of $548.88M
- PositionCurrent ratio is 0.93×, lower than 95% of its Biotechnology peers (median 5.71×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.12%Above 5Y avg (2.20%)
Annual Rate
KRW 300.00Paid annual
Payout Ratio
0.0%Sustainable
Payback Period
32.3 yr
Last Ex-Dividend
Mar 30, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
434.96BKRW316.87M · vs all stocks (USD)
Revenue (TTM)
2.49TKRW1.81B · vs all stocks (USD)
Profit Margin
-4.91%vs Biotechnology peers
Beta
0.5660xvs all stocks
52-Week Change
-43.18%vs all stocks
Market Capitalization
434.96BKRW316.87M · vs all stocks (USD)
Enterprise Value
2.89TKRW2.10B · vs all stocks (USD)
Price to Sales (TTM)
0.1749xvs Biotechnology peers
Price to Book (MRQ)
0.2510xvs Biotechnology peers
Enterprise to Revenue
1.16xvs Biotechnology peers
Enterprise to EBITDA
21.07xvs Biotechnology peers
Gross Margin
28.78%vs Biotechnology peers
Profit Margin
-4.91%vs Biotechnology peers
Operating Margin
1.11%vs Biotechnology peers
Return on Assets (TTM)
0.44%vs Biotechnology peers
Return on Equity (TTM)
-8.38%vs Biotechnology peers
Revenue (TTM)
2.49TKRW1.81B · vs all stocks (USD)
Revenue per Share (TTM)
55.64KKRWUpdated Sep 21, 2026Quarterly Revenue Growth
-0.70%vs Biotechnology peers
Gross Profit (TTM)
679.07BKRW494.70M · vs all stocks (USD)
EBITDA (TTM)
132.94BKRW96.85M · vs all stocks (USD)
Net Income (TTM)
-121.26BKRW-88.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-95.40%vs Biotechnology peers
Operating Cash Flow (TTM)
164.17BKRW119.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.84BKRW-1.34M · vs all stocks (USD)
Trailing Annual Dividend Rate
300.00KRWUpdated Sep 21, 2026Trailing Annual Dividend Yield
3.12%vs all stocks
5-Year Average Dividend Yield
2.20%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
862.84BKRWFY2025 · Dec 31, 2025Revenue
2.45TKRWFY2025 · Dec 31, 2025Cost of Goods Sold
1.77TKRWFY2025 · Dec 31, 2025Gross Profit
682.74BKRWFY2025 · Dec 31, 2025Operating Income
36.46BKRW26.56M · vs all stocks (USD)
Pre-tax Income
-53.44BKRWFY2025 · Dec 31, 2025Income Tax Expense
-11.62BKRWFY2025 · Dec 31, 2025Net Income
-41.82BKRWFY2025 · Dec 31, 2025EBIT
18.56BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
225.77BKRWFY2025 · Dec 31, 2025Research & Development
157.26BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
228.44BKRWFY2025 · Dec 31, 2025Other Operating Expenses
9.62BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
5.54BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
72.00BKRWFY2025 · Dec 31, 2025EPS (Basic)
-1.53KKRWFY2025 · Dec 31, 2025EPS (Diluted)
-1.53KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
45.40MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
45.40MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.82BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-27.69BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-16.37BKRWFY2025 · Dec 31, 2025Free Cash Flow
-123.67BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
79.66BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.82BKRWFY2025 · Dec 31, 2025Other Non-cash Items
67.18BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-38.12BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.62BKRWFY2025 · Dec 31, 2025Capital Expenditures
-107.30BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-34.51BKRWFY2025 · Dec 31, 2025Net Acquisitions
-134.27BKRWFY2025 · Dec 31, 2025Purchase of Investments
-92.14BKRWFY2025 · Dec 31, 2025Sale of Investments
113.75BKRWFY2025 · Dec 31, 2025Other Investing Activity
10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-219.96BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
408.70BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-1.76TKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-43.20BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-33.21BKRWFY2025 · Dec 31, 2025Other Financing Charges
-96.28BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.53TKRWFY2025 · Dec 31, 2025Shares Outstanding
44.97MSharesUpdated Sep 21, 2026Float Shares
24.41MSharesUpdated Sep 21, 2026% Held by Insiders
49.83%vs all stocks
% Held by Institutions
9.45%vs all stocks
Total Cash (MRQ)
107.82BKRW78.54M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.40KKRWUpdated Sep 21, 2026Total Debt (MRQ)
1.69TKRW1.23B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9706xvs Biotechnology peers
Current Ratio (MRQ)
0.9310xvs Biotechnology peers
Book Value per Share (MRQ)
38.33KKRWUpdated Sep 21, 2026Total Assets
4.07TKRW2.96B · vs all stocks (USD)
Total Current Assets
1.55TKRWFY2025 · Dec 31, 2025Total Liabilities
2.31TKRWFY2025 · Dec 31, 2025Total Non-current Assets
2.52TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
697.40BKRWFY2025 · Dec 31, 2025Total Current Liabilities
1.61TKRWFY2025 · Dec 31, 2025Cash
79.66BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
79.66BKRWFY2025 · Dec 31, 2025Other Short-term Investments
19.63BKRWFY2025 · Dec 31, 2025Accounts Receivable
477.92BKRWFY2025 · Dec 31, 2025Inventory
909.80BKRWFY2025 · Dec 31, 2025Accounts Payable
222.52BKRWFY2025 · Dec 31, 2025Short-term Debt
909.46BKRWFY2025 · Dec 31, 2025Other Current Liabilities
48.74BKRWFY2025 · Dec 31, 2025Long-term Debt
583.83BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
20.98BKRWFY2025 · Dec 31, 2025Common Stock (Book)
25.32BKRWFY2025 · Dec 31, 2025Retained Earnings
806.79BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
1.76TKRW1.28B · vs all stocks (USD)
Treasury Stock
18.15BKRWFY2025 · Dec 31, 202552-Week Low
8.63KKRWUpdated Sep 21, 202652-Week High
18.01KKRWUpdated Sep 21, 202652-Week Change
-43.18%vs all stocks
Beta
0.5660xvs all stocks
50-Day MA
9.86KKRWUpdated Sep 21, 2026200-Day MA
13.13KKRWUpdated Sep 21, 2026Avg 10-Day Volume
50.21KSharesUpdated Sep 21, 2026Avg 30-Day Volume
100.36KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-1.53KKRWUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.93×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.93Industry median: 5.71Industry P5: 1.02Peers compared: 260
Debt-to-equity is 0.97×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 0.97Industry median: 0.07Industry P95: 0.93Peers compared: 260
Price-to-book is 0.25×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.25Industry median: 2.86Industry P5: 0.98Peers compared: 260
Financial Health
Altman Z-Score 0.99: distress zoneCritical
Altman Z-Score: 0.99
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.81B, above the global median of $548.88MNotable
Revenue (USD): 1,812,063,456.199Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Edan Instruments Inc.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Yamaichi Electronics Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Guangdong Silver Age Sci & Tech Co. Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated